ClinicalTrials.gg
CompletedNCT02652806Updated Aug 24, 2017

FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease

A Phase 3 interventional study of FG-4592 and Epoetin Alfa in Anemia, sponsored by FibroGen. Completed at 31 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-08-24.

Sponsored by FibroGen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
305
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
11th of 43
305 · median 154
Started
2015
with 2 others
Phase 3
25 of 43
1 open now
Registered
17th of 43
by date
Lead sponsor
20 of 43
FibroGen

Among the 43 studies testing roxadustat in Anemia, this one is the 11th largest by enrollment, is one of 3 that started in 2015, is one of 25 in phase 3, and was the 17th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

This is a randomized, multicenter, open-label, active-controlled study of the treatment of anemia in subjects with CKD on dialysis, with treatment up to 52 weeks.

Read the detailed description

This is a randomized, multicenter, open-label, active-controlled study of the treatment of anemia in subjects with CKD on dialysis. Eligible subjects are randomized to FG-4592 or epoetin alfa at a ratio of 2:1. The primary endpoint is Hb mean change from baseline averaged over Weeks 23 to 27.

03

Conditions studied

  • Anemia

Keywords

  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ages 18 to 75 years
  2. Subject has voluntarily signed and dated an form (ICF), approved by an Ethics Committee (EC), after the nature of the study has been explained and the subject has had the opportunity to ask questions; a separate ICF is needed for subjects participating in the PK Sub-study.
  3. "Chronic kidney disease with end-stage renal disease (ESRD) on either adequate hemodialysis (HD) or adequate peritoneal dialysis for a minimum of 16 weeks prior to Day 1: For subjects undergoing HD, the vascular access must be via native arteriovenous (AV) fistula or graft, or permanent, tunneled catheter."
  4. Subjects must be on stable doses of IV or subcutaneous (SC) injections of epoetin alfa for at least 6 weeks prior to Day 1 (average dose ≤15,000 IU/week)
  5. Mean of the two most recent central laboratory values during the Screening Period, obtained at least 6 days apart, must be 9.0 g/dL to 12.0 g/dL, inclusive, with a difference of \≤1.5 g/dL between the highest and the lowest Hb values.
  6. (ALT) and aspartate aminotransferase (AST) ≤1.5 x (ULN), and normal total at screening visit except for subjects with Gilberts syndrome (based on central laboratory results).
  7. Body weight: 45 to 100 kg inclusive 8 Subjects agree not to start taking any new Traditional Chinese Medicine (TCM) for anemia and not to change dose, schedule, or brand of any prescreening TCM for anemia from beginning of Screening Period through end of Follow-up Period.

Exclusion criteria

Exclusion Criteria:

  1. Any infection or evidence of an active underlying infection.
  2. Positive for any of the following: (HIV), surface antigen (HBsAg), or anti- virus antibody (anti-HCV Ab).
  3. Chronic liver disease.
  4. Class III or IV congestive heart failure.
  5. Myocardial infarction, acute coronary syndrome, stroke, seizure, or a thromboembolic event (eg, deep venous thrombosis or pulmonary embolism) within 52 weeks prior to Day 1.
  6. Uncontrolled hypertension in the opinion of the investigator (eg, that requires change in anti-hypertensive medication within 2 weeks prior to randomization).
  7. Diagnosis or suspicion (eg, complex kidney cyst of Bosniak Category II or higher) of renal cell carcinoma as shown on screening renal ultrasound.
  8. History of except the following: cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell skin cancers, or in situ cancer at any site.
  9. Chronic inflammatory disease other than glomerulonephritis that could impact erythropoiesis (eg, systemic lupus erythematosis [SLE], rheumatoid arthritis, celiac disease).
  10. Clinically significant gastrointestinal bleeding.
  11. Known history of myelodysplastic syndrome, multiple myeloma, hereditary hematologic disease such as thalassemia, sickle cell anemia, pure red cell aplasia, or other known causes for anemia other than CKD, hemosiderosis, hemochromatosis, known coagulation disorder, or hypercoagulable condition.
  12. Any prior functioning organ transplant or a scheduled organ transplantation, or anephric.
  13. Anticipated elective surgery that could lead to significant blood loss during the study period.
  14. Anticipated use of dapsone or acetaminophen (paracetamol) >2.0 g/day, or >500 mg per dose repeated every 6 hours for more than 3 days.
  15. Serum albumin \<2.5 g/dL.
  16. Androgen, deferoxamine, deferiprone, or deferasirox therapy within 12 weeks prior to Day 1.
  17. of \<12 months.
  18. Blood transfusion within 12 weeks prior to Day 1 or anticipated need for transfusion.
  19. IV iron supplement during the Screening Period and /or unwilling to withhold IV iron.
  20. Immune suppressive or systematic treatment within 12 weeks prior to Day 1.
  21. History of alcohol or drug abuse within the past 2 years and inability to avoid consumption of more than >3 alcoholic beverages per day.
  22. Prior treatment with FG-4592 or any hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI).
  23. Use of an medication or treatment, participation in an investigational interventional study, or carryover effect of an investigational treatment expected during the study.
  24. Women who are pregnant or breastfeeding.
  25. Women of and men with sexual partners of child bearing potential who are not using adequate .
  26. Any medical condition that, in the opinion of the investigator, may pose a safety risk to a subject in this study, may confound efficacy or safety assessment, or may interfere with study participation.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
305 participants (actual)

Study arms

  • Experimental
    FG-4592

    Intervention is investigational treatment FG-4592

    Drug: FG-4592

  • Active comparator
    EPO

    Intervention is subject's current dose of Li Xue Bao (epoetin alfa)

    Drug: Epoetin Alfa

Interventions

06

What researchers measure

Primary outcomes

  1. Hb mean change from baseline

    Hb mean change from baseline

    Time frame: Weeks 23 to 27.

Secondary outcomes

  1. Mean change from baseline in low-density lipoprotein (LDL) cholesterol

    Mean change from baseline in low-density lipoprotein (LDL) cholesterol

    Time frame: Weeks 25-27

  2. Number of subjects with a Hb response

    Number of subjects with a Hb response (as defined per protocol)

    Time frame: Weeks 23-27

  3. Percent of subjects with a Hb response

    Percent of subjects with a Hb response (as defined per protocol)

    Time frame: Weeks 23-27

  4. Effect on iron metabolism

    Measurement of serum iron

    Time frame: Week 27

  5. Proportion of subjects with exacerbation of hypertension

    Proportion of subjects with exacerbation of hypertension, meeting at least one of the following criteria up to Week 27: * Increase in anti-hypertensive medication use, * Adverse event of hypertension, or * Increases from baseline in blood pressure confirmed by repeat measurement at next visit unless anti-hypertensive medications are changed.

    Time frame: Up to Week 27

  6. Mean change from baseline in predialysis and postdialysis mean arterial blood pressure

    Mean arterial blood pressure measured pre-and post-dialysis.

    Time frame: Weeks 23-27

  7. Number of subjects with treatment-emergent adverse events (TEAEs).

    Number of subjects with treatment-emergent adverse events (TEAEs).

    Time frame: Week 1 to up to Week 53

  8. Percent of subjects with treatment-emergent adverse events (TEAEs).

    Percent of subjects with treatment-emergent adverse events (TEAEs).

    Time frame: Week 1 to up to Week 53

  9. Changes from baseline in vital signs

    Measurement of vital signs

    Time frame: Week 1 to up to Week 53

  10. Changes from baseline in ECG findings.

    ECG recordings.

    Time frame: Week 1 to up to Week 53

  11. Changes from baseline in clinical laboratory values.

    Clinical laboratory values.

    Time frame: Week 1 to up to Week 53

  12. Number and % of subjects on rescue therapy during study treatment.

    Number and % of subjects on rescue therapy during study treatment.

    Time frame: Week 1 to up to Week 53

  13. Time to rescue therapy from date of first dose during study treatment.

    Time to rescue therapy from date of first dose during study treatment.

    Time frame: Week 1 to up to Week 53

07

Study locations

31 sites
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui, China
  • 301 Hospital
    Beijing, Beijing, China
  • Peking Union Medical College Hospital
    Beijing, Beijing, China
  • Peking University First Hospital
    Beijing, Beijing, China
  • Peking University Third Hospital
    Beijing, Beijing, China
  • Pekingg University, People's Hospital
    Beijing, Beijing, China
  • The First Affiliated hospital of Third Military Medical University (Southwest Hospital)
    Chongqing, Chongqing, China
  • Lan Zhou University Second Hospital
    Lanzhou, Gansu, China
  • Guangdong General Hospital
    Guangzhou, Guangdong, China
  • Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong, China
  • Shenzhen People's Hospital
    Shenzhen, Guangdong, China
  • The First Affiliated hospital of Guangxi Medical University
    Nanning, Guangxi, China
  • The People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The First Hospital of Baotou Medical School of Inner Mongolia University of Science and Technology
    Baotou, Inner Mongolia, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu, China
  • Nanjing General Hospital of Nanjing Military Command
    Nanjing, Jiangsu, China
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi, China
  • Shandong Provincial Hospital
    Jinan, Shandong, China
  • Rui Jin Hospital Shanghai Jiao Tong University School of Medication
    Shanghai, Shanghai 200025, China
  • Huashan Hospital of Fudan University
    Shanghai, Shanghai 200040, China
  • Shanghai Changzheng Hospital
    Shanghai, Shanghai, China
  • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medication
    Shanghai, Shanghai, China
  • The Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • West China Hospital, Sichuan Universtiy
    Chengdu, Sichuan, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin, China
  • The First Affiliated Hospital, Zhejiang University
    Hangzhou, Zhejiang, China
  • Ningbo No.2 Hospital
    Ningbo, Zhejiang, China
08

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C, Liang X, Jiang G, Liu Z, Li X, Zuo L, Luo L, Wang J, Zhao MH, Liu Z, Cai GY, Hao L, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. N Engl J Med. 2019 Sep 12;381(11):1011-1022. doi: 10.1056/NEJMoa1901713. Epub 2019 Jul 24. PubMed 31340116 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Jan 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2015
First posted
Jan 12, 2016
Start
Dec 2015
Primary completionActual
Jan 24, 2017
CompletionActual
Jun 14, 2017
Last update
Aug 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02652806
Lead sponsor
FibroGen
Responsible party
Sponsor
First posted
Jan 12, 2016
Start date
Dec 2015
Primary completion
Jan 24, 2017
Completion
Jun 14, 2017
Last update
Aug 24, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion